SCHEMBL19348474

SCHEMBL19348474

COc1ccc(C(=O)Nc2cc(OC)c(OC)c(OC)c2C(=O)NCCN2CCN(C)CC2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.56
ALDH1A1 P00352 2/20 0.55
GAA P10253 2/20 0.55
BCL3 P20749 1/20 0.55
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
CYP2D6 P10635 1/20 0.54
CYP2C9 P11712 1/20 0.54
CYP2C19 P33261 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.52
HDAC2 Q92769 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
DRD4 P21917 1/20 0.48
F10 P00742 2/20 0.48
LMNA P02545 1/20 0.48
SLC29A1 Q99808 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554049 0.90 ALDH1A1 (0.68) POLBALDH1A1GAABCL3KMT2A
SCHEMBL17554013 0.87 ALDH1A1 (0.62) POLBALDH1A1GAABCL3KMT2A
SCHEMBL17554157 0.84 ALDH1A1 (0.52) POLBALDH1A1CYP1A2CYP2C19SMN1; SMN2
SCHEMBL17554018 0.82 BCL3 (0.57) POLBALDH1A1BCL3KMT2AMEN1
SCHEMBL17554033 0.81 SLC29A1 (0.54) POLBALDH1A1GAABCL3KMT2A
SCHEMBL17554150 0.81 ALDH1A1 (0.81) POLBALDH1A1GAABCL3KMT2A
SCHEMBL17554111 0.80 ALDH1A1 (0.60) POLBALDH1A1GAABCL3KMT2A
SCHEMBL6352503 0.77 POLB (0.71) POLBALDH1A1GAABCL3CYP1A2
SCHEMBL17554145 0.77 ALDH1A1 (0.61) POLBALDH1A1GAABCL3KMT2A
SCHEMBL17554173 0.75 SMN1; SMN2 (0.57) ALDH1A1GAABCL3KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248756-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 POLB 1797/4885ALDH1A1 2635/4885GAA 4322/4885
US-10273218-B2 BCL-3 inhibitors BCL3, BCL2, BCL2L13 POLB 1339/4885ALDH1A1 2830/4885GAA 4220/4885
US-20170267653-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 POLB 1339/4885ALDH1A1 2830/4885GAA 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.